|
May 3
|
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
|
|
May 2
|
Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
|
|
May 2
|
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
|
|
Apr 30
|
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
|
|
Apr 30
|
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
|
|
Apr 25
|
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
|
|
Apr 16
|
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
|
|
Apr 15
|
Ultragenyx says Angelman therapy is working, but safety questions remain
|
|
Apr 15
|
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
|
|
Apr 12
|
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
|
|
Apr 12
|
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
|
|
Mar 20
|
10 NASDAQ Stocks with Biggest Upside
|
|
Mar 12
|
Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
|
|
Mar 11
|
Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
|
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
|
Jan 25
|
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
|
|
Jan 9
|
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
|
|
Jan 7
|
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
|
|
Jan 4
|
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
|
|
Jan 4
|
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
|